Heart failure & cardiomyopathiesSecondary analysis
Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
- Secondary analysis of the FINEARTS-HF randomised trial
- double-blind
Authors' conclusion
In a large HFmrEF/HFpEF trial population, clinically meaningful changes in readily available biomarkers, functional status, and patient-reported health status were observed in the months leading up to a clinical event.
Study context
- Population
- Patients with symptomatic HF and LVEF ≥40% (HFmrEF/HFpEF) in the FINEARTS-HF trial of finerenone vs placebo1,343 events
- Participants
- 6,001 patients
- Comparison
- Patients with a clinical event vs event-free controls
- Primary endpoint
- Temporal patterns of NT-proBNP, eGFR, NYHA class, KCCQ-TSS and diuretic dose before CV death or first HF event
Primary result
As reported in the abstract
median 2.7-year follow-up
Diuretic dose increased in the 6 months before an event (furosemide equivalents)
∼50 to ∼60 mg/day
Further findings
Baseline characteristics, event vs control
- Event patients had higher NT-proBNP, lower eGFR, higher NYHA class, lower KCCQ-TSS and higher diuretic doses
Original publication
Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Fail. Published 25 August 2025. doi:10.1016/j.jchf.2025.102590
Summarised from the published abstract; every number is checked against it